Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

• Published in: Psychopharmacologia Vol. 167; no. 4; pp. 443 - 448
• Main Authors: Gerstenberg, Gisa, Aoshima, Toshiaki, Fukasawa, Takashi, Yoshida, Keizo, Takahashi, Hitoshi, Higuchi, Hisashi, Murata, Yoshiko, Shimoyama, Ritsuko, Ohkubo, Tadashi, Shimizu, Tetsuo, Otani, Koichi
• Format: Journal Article
• Language: English
• Published: Berlin Springer Science and Business Media LLC 01.06.2003; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Amino Acids; Amino Acids - blood; Antidepressive Agents, Second-Generation; Antidepressive Agents, Second-Generation - blood; Antidepressive Agents, Second-Generation - therapeutic use; Biological and medical sciences; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 - metabolism; Depressive Disorder, Major; Depressive Disorder, Major - blood; Depressive Disorder, Major - drug therapy; Dose-Response Relationship, Drug; Female; Fluvoxamine; Fluvoxamine - analogs & derivatives; Fluvoxamine - blood; Fluvoxamine - therapeutic use; Humans; Japan; Male; Medical sciences; Middle Aged; Neuropharmacology; Pharmacology. Drug treatments; Psychiatric Status Rating Scales; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Selective Serotonin Reuptake Inhibitors; Serotonin Uptake Inhibitors - blood; Serotonin Uptake Inhibitors - therapeutic use; Smoking; Treatment Outcome; Japan; Mood disorder; Human; Pharmacokinetic pharmacodynamic relationship; Serotonin; Enzyme; Isozyme; Metabolite; Psychotropic; Fluvoxamino acid; Cytochrome P450; Oral administration; Depression; Reuptake inhibitor; Clinical effects; Japanese; Chemotherapy; Treatment; Activity concentration relation; Steady-state plasma concentration; CYP2D6; Concentration metabolism relation; Antidepressant agent; Pharmacokinetics; Fluvoxamine
• ISSN: 0033-3158; 1432-2072
• DOI: 10.1007/s00213-003-1430-1

The relationship between clinical effects of fluvoxamine (FLV) and the steady-state plasma concentrations (Css) of FLV and its major metabolite fluvoxamino acid (FLA) was studied. The subjects were 49 Japanese patients with major depressive disorder receiving FLV 200 mg/day for 6 weeks. Depressive s...